VivoSeq
Dermatology

Skin Ulcer

5

Pipeline Programs↗

3

Active Trials↗

4

Companies Involved↗

Skin ulcer is an early-stage landscape with 5 programs across 4 companies. The most active players are Novo Nordisk, Milestone Pharmaceuticals Inc., Viatris Specialty LLC. 2 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

30/100

Pipeline Velocity

11/100

Mech. Concentration

33/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novo Nordisk logo

Novo Nordisk

1 program

Phase 1M

Milestone Pharmaceuticals Inc.

1 program

ApprovedV

Viatris Specialty LLC

1 program

ApprovedS

Sequence LifeScience, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

86%

Small molecule

6 of 7 classified programs — the dominant modality here.

14%ALL OTHERSCell therapy114%

Small molecule leads; the ring shows all 7 classified programs, each share of the total. Modality classified for 100% of 8 pipeline programs.

Analysis

Trial Status

4

clinical trials

Recruiting2 · 50%
Completed1 · 25%
Not yet recruiting1 · 25%

Clinical Trials

Trial Activity

UC-MSCs Gel Treatment Difficult Healing of Skin Ulcers
Completed·—·Phase 1·NCT02685722·20 enrolled
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Skin Ulcer
Not yet recruiting·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05158127·20 enrolled
Acetic Acid 2% Solution for Skin Ulcers
Recruiting·CConsorci Sanitari de l'Alt Penedès i Garraf·Phase 3·NCT06297967·104 enrolled
Study Title: A Multicenter, Prospective, Modified Platform Trial Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Matched Standard of Care Controls in the Management of Nonhealing Pressure Ulcers.
Recruiting·SSequence LifeScience, Inc.·Approved·NCT07665268·2,000 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)